Eosinophilic Gastroenteritis

Comprehensive Clinical Guide: Eosinophilic Gastroenteritis (EGE)

1. Introduction and Overview

Eosinophilic Gastroenteritis (EGE) is a rare, complex, and chronic gastrointestinal disorder characterized by eosinophilic infiltration of the bowel wall, often associated with peripheral blood eosinophilia. Unlike common gastrointestinal conditions, EGE is a distinct clinicopathological entity that can affect any segment of the gastrointestinal tract, from the esophagus to the rectum.

As an immune-mediated disorder, EGE represents a significant diagnostic challenge due to its heterogeneous clinical presentation, which depends heavily on the layer of the gut wall involved (mucosal, muscular, or serosal). While historically considered a rare disease, increased clinical awareness and improved endoscopic diagnostic techniques have led to higher detection rates. This guide provides an exhaustive clinical overview for medical practitioners and specialists.

2. Etiology and Pathophysiology

The precise etiology of EGE remains multifactorial, involving an interplay between genetic predisposition, environmental triggers, and dysregulated immune responses.

The Th2-Mediated Mechanism

EGE is fundamentally driven by a Type 2 helper T-cell (Th2) immune response. The pathophysiology involves:
* Antigenic Triggering: Food allergens or environmental aeroallergens are hypothesized to initiate the cascade in genetically susceptible individuals.
* Cytokine Release: Activated T-cells release IL-3, IL-5, and GM-CSF.
* Eosinophil Recruitment: IL-5 is the primary cytokine responsible for the maturation, activation, and chemotaxis of eosinophils from the bone marrow to the gastrointestinal mucosa.
* Tissue Damage: Eosinophils release cytotoxic granules, including Major Basic Protein (MBP), Eosinophil Peroxidase (EPO), and Eosinophil-Derived Neurotoxin (EDN), which cause mucosal inflammation, smooth muscle hypertrophy, or serosal exudation.

Classification by Depth of Involvement (Klein’s Classification)

The clinical phenotype is dictated by the depth of eosinophilic infiltration:

3. Clinical Presentation and Staging

The clinical manifestation is often insidious, leading to significant diagnostic delays. Patients frequently present with symptoms that mimic other common GI disorders, such as IBD or Irritable Bowel Syndrome (IBS).

Standard Symptomatology

• Gastrointestinal: Chronic abdominal pain, nausea, vomiting, early satiety, diarrhea, and weight loss.
• Systemic: Fatigue, failure to thrive (in pediatrics), and peripheral eosinophilia (present in ~50-70% of cases).
• Specific Presentations:
  • Mucosal: Iron deficiency anemia, hypoalbuminemia, and steatorrhea.
  • Muscular: Post-prandial vomiting and radiographic evidence of bowel wall thickening.
  • Serosal: Significant ascites containing high eosinophil counts.

4. Diagnostic Workup and Key Investigations

Diagnosis of EGE requires a high index of suspicion, as no single non-invasive test is pathognomonic.

The Diagnostic Triad

1. Gastrointestinal Symptoms: Consistent with the anatomical involvement.
2. Histologic Evidence: Eosinophilic infiltration of the GI tract (usually defined as >20-30 eosinophils per high-power field (HPF) in at least one biopsy site).
3. Exclusion: Absence of other causes of eosinophilia (parasitic infections, malignancy, vasculitis, or drug-induced reactions).

Diagnostic Tools

• Endoscopy (EGD/Colonoscopy): Essential for visualizing mucosal changes (edema, erythema, friability, or nodules) and obtaining multiple targeted biopsies.
• Histopathology: Biopsies must be taken from both symptomatic and asymptomatic areas, as the disease is often "patchy."
• Laboratory Analysis: Complete Blood Count (CBC) with differential to assess peripheral eosinophilia, serum albumin, and total IgE levels.
• Radiology: CT or MRI enterography is vital for detecting bowel wall thickening, strictures, or ascites, particularly in muscular and serosal variants.

5. Differential Diagnosis

Clinicians must systematically rule out secondary causes of eosinophilic infiltration:
* Parasitic Infections: Strongyloides, Toxocara, Anisakis. (Always check stool O&P).
* Inflammatory Bowel Disease: Crohn’s disease can also show increased eosinophils.
* Connective Tissue Disorders: Eosinophilic granulomatosis with polyangiitis (EGPA).
* Malignancy: T-cell lymphoma, hypereosinophilic syndrome (HES).
* Drug Hypersensitivity: NSAIDs or antibiotics.

6. Therapeutic Management

Management is aimed at reducing inflammation, managing nutritional deficits, and preventing complications.

First-Line Therapies

1. Dietary Elimination:
   • Elemental Diet: Highly effective but difficult to maintain; amino-acid-based formulas.
   • Empiric Elimination Diet: Removing common allergens (dairy, soy, wheat, eggs, nuts, seafood).
2. Corticosteroids:
   • Systemic Prednisone (0.5–1 mg/kg/day) is the gold standard for acute flares, typically showing rapid symptomatic relief.
   • Challenge: High risk of relapse upon tapering.

Second-Line and Maintenance

• Mast Cell Stabilizers: Cromolyn sodium may help prevent eosinophil degranulation.
• Biologics: Emerging evidence for Mepolizumab (anti-IL-5) or Dupilumab (anti-IL-4/IL-13) in refractory cases.
• Immunomodulators: Azathioprine or 6-mercaptopurine for steroid-sparing maintenance.

7. Risks, Side Effects, and Contraindications

• Steroid Toxicity: Long-term use of corticosteroids carries risks of osteoporosis, diabetes, cataracts, and immunosuppression.
• Nutritional Deficiency: Over-restrictive diets can lead to severe malnutrition and electrolyte imbalances if not supervised by a specialized dietitian.
• Endoscopic Risks: While generally safe, deep biopsies in the setting of severe inflammation carry a marginal risk of perforation.

8. Long-term Prognosis

EGE is typically a chronic, relapsing-remitting condition. While it is rarely fatal, the quality of life can be significantly impacted by chronic pain and dietary restrictions.
* Remission: Many patients achieve clinical remission with dietary management or long-term low-dose maintenance therapy.
* Complications: Prolonged untreated disease can lead to bowel obstruction, strictures requiring surgical intervention, or severe protein-losing enteropathy.

9. Frequently Asked Questions (FAQ)

1. Is Eosinophilic Gastroenteritis an autoimmune disease?
It is classified as an immune-mediated disorder. While the body attacks its own tissues, it is primarily driven by allergic-type (Th2) inflammation rather than the classical autoimmune mechanisms seen in Lupus or Rheumatoid Arthritis.

2. Can EGE be cured?
There is no "cure" in the traditional sense, but it can be managed effectively. Many patients achieve long-term remission through diet and medication.

3. What is the difference between EGE and Eosinophilic Esophagitis (EoE)?
EoE is localized to the esophagus, whereas EGE involves the stomach or intestines. EGE is generally considered more systemic and can be more difficult to manage.

4. How many biopsies are needed for a diagnosis?
Because the disease is patchy, experts recommend at least 6–8 biopsies from multiple sites, including both the stomach and the duodenum, even if the mucosa appears normal.

5. Does peripheral blood eosinophilia confirm the diagnosis?
No. Peripheral eosinophilia is absent in 30–50% of EGE cases. A normal blood count does not rule out the disease.

6. Are food allergies the only cause?
While food allergies are a major trigger, environmental factors and genetic predispositions play a significant role. EGE is not a simple "food allergy" in the sense of an IgE-mediated anaphylactic reaction.

7. Can EGE lead to cancer?
There is no strong evidence linking EGE to an increased risk of gastrointestinal malignancy, though chronic inflammation is always a clinical concern.

8. Is surgery required for EGE?
Surgery is generally reserved for complications such as bowel obstruction, perforation, or strictures that do not respond to medical management.

9. What is the role of the dietitian in EGE treatment?
A specialized dietitian is crucial for managing the complex elimination diets required for diagnosis and maintenance, ensuring the patient avoids malnutrition.

10. How often should patients be monitored?
Patients should undergo regular clinical follow-ups every 3–6 months during the active phase, with repeat endoscopies as needed to assess histological healing.

10. Summary for Clinical Practice

Eosinophilic Gastroenteritis requires a multidisciplinary approach involving gastroenterologists, pathologists, allergists, and nutritionists. Clinicians should maintain a low threshold for biopsy in patients with unexplained abdominal symptoms, particularly those with a history of atopy or peripheral eosinophilia. By focusing on identifying the underlying trigger and utilizing a step-up approach to therapy—starting with diet and escalating to biologics—the majority of patients can achieve a high quality of life and symptomatic control.

Disclaimer: This guide is intended for educational purposes for healthcare professionals and does not replace institutional clinical protocols or individual patient assessment. Always consult the latest clinical guidelines from the American College of Gastroenterology (ACG) or equivalent international bodies.